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OBJECTIVES This study was designed to compare the efficacy of low and intermediate aspirin doses in acute
coronary syndromes.
BACKGROUND Little is known of the comparative efficacy of low and intermediate aspirin doses in this
setting.
METHODS We compared six-month death, myocardial infarction (MI), and stroke in patients with
unstable angina or acute MI discharged while receiving low (150 mg) or intermediate
(150 mg) aspirin therapy in the GUSTO IIb and PURSUIT trials (n  20,521). We used
multivariable analysis and performed a propensity analysis in order to adjust for baseline
imbalances between the groups.
RESULTS Aspirin doses 150 mg were prescribed to 29.9% (6,128) of patients. By six months, 6.4%
of the patients (1,310 of 20,521) had a primary event, 6.2% of the patients receiving150 mg
and 6.6% of the patients receiving aspirin doses 150 mg (hazard ratio [HR] 1.06 [95%
confidence interval (CI) 0.94 to 1.19], p  0.35). After adjusting for baseline imbalances and
the propensity score for discharge aspirin dose, there was no effect of aspirin dose on the
composite end point at six months (HR 0.92 [95% CI 0.79 to 1.07], p 0.28). However, the
higher aspirin dose was associated with a reduction in six-month MI (HR 0.79 [95% CI 0.64
to 0.98], p 0.03). The outcome was similar when patients were matched on the basis of the
propensity score for aspirin dose (HR for death/MI/stroke 0.94 [95% CI 0.80 to 1.12], p 
0.51), although stroke occurred significantly more frequently among patients receiving the
higher aspirin dose (HR 1.74 [95% CI 1.01 to 3.02] p  0.05) and the effect on MI was no
longer apparent.
CONCLUSIONS Although these data are non-randomized, they suggest that the aspirin dose upon discharge
may influence the clinical course after unstable angina or acute MI. (J Am Coll Cardiol
2004;43:972–8) © 2004 by the American College of Cardiology FoundationH
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che antiplatelet agent aspirin provides marked protection
rom vascular events in a broad spectrum of patients with
therosclerotic disease. In a recent meta-analysis of 287
rials in more than 210,000 patients, aspirin prevented 25
erious vascular events (vascular death, myocardial infarction
MI], or stroke) per thousand patients treated (1). The dose
f aspirin studied in these trials varied from 20 mg to 1,500
g, and the proportional reduction in risk was similar for
oses of 75 to 150 mg, 160 to 325 mg, and 500 to 1,500 mg.
spirin doses between 75 and 325 mg are currently recom-
ended by the European Heart Association, the American
ollege of Cardiology, and the American Heart Association
or the management of patients with acute coronary syn-
romes (ACS) (2,3). Doses in the lower end of this range
re often preferred to limit gastrointestinal side effects (4).
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f Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio;
The Duke Clinical Research Institute, Durham, North Carolina; and the Baylor
ollege of Medicine, Houston, Texas.
Manuscript received July 9, 2003; revised manuscript received September 12, 2003,iccepted September 29, 2003.owever, little is known of the comparative efficacy of
spirin doses within this range in patients with ACS. The
vidence to support the equivalent efficacy of aspirin doses
etween 75 and 325 mg is mainly drawn from indirect
omparisons between trials of different aspirin dose and
irect comparisons in patients with cerebrovascular (5–7) or
eripheral vascular (8) disease. There have been only two
mall direct comparisons of low and intermediate aspirin
oses in patients with ACS, only one of which has been
ublished (9). These failed to detect an effect of aspirin dose
n outcome; however, they had extremely limited statistical
ower to do so. Furthermore, the assumption that low-dose
spirin has equivalent efficacy in different vascular beds may
ot be entirely valid. Platelet activation is enhanced in
atients with unstable angina or acute MI (10), and the risk
f recurrent ischemic events in this population is high. The
henomenon of “aspirin resistance,” defined as failure to
chieve adequate suppression of biochemical markers of
spirin’s inhibition, is observed in up to 20% (11,12) of
atients with ACS and has recently been linked to adverse
linical outcome (13,14). There is some evidence that
ncreasing aspirin dose, even within the range 75 to 300 mg
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March 17, 2004:972–8 Aspirin Dose in Acute Coronary Syndromes15,16), may overcome biochemical evidence of aspirin
esistance and thus may alter clinical outcome. In order to
ddress this issue we compared six-month ischemic events
n patients discharged while receiving low (150 mg) and
ntermediate (150 mg) aspirin therapy in the Global Use
f Strategies to open Occluded coronary Arteries (GUSTO)
Ib and Platelet Glycoprotein IIb/IIIa in Unstable Angina:
eceptor Suppression Using Integrelin Therapy (PUR-
UIT) trials.
ETHODS
atient population. The GUSTO IIb and PURSUIT
rials have been described previously (17,18). Briefly, these
ere large randomized trials in patients with ACS. The
USTO IIb (n  12,142) trial recruited patients with
on–ST- or ST-segment elevation MI or unstable angina
hereas the PURSUIT (n  10,948) trial enrolled patients
ith non–ST-segment elevation ACS. In GUSTO IIb
atients were required to have chest pain within 12 h of
nrollment associated with electrocardiographic (ECG)
hanges. In PURSUIT patients were recruited within 24 h
f their last episode of chest pain at rest and were required
o have ECG changes or elevation of creatine kinase-MB
raction. Only patients who survived to hospital discharge
ere included in this analysis. In GUSTO IIb 495 patients
ied before hospital discharge, whereas in PURSUIT 324
ied before discharge.
reatment. In GUSTO IIb patients were randomized to
ntravenous unfractionated heparin or the direct thrombin
nhibitor hirudin. Thrombolytic therapy, either streptoki-
ase or an accelerated infusion of tissue plasminogen acti-
ator, was given to patients with ST-segment elevation at
he discretion of the treating physician. In PURSUIT
atients were randomized to one of two doses of the
ntravenous platelet glycoprotein IIb/IIIa receptor antago-
Abbreviations and Acronyms
ACS  acute coronary syndrome
ALDUSA  Aspirin at Low Dose in Unstable Angina
ATACS  Antithrombotic therapy in Acute
Coronary Syndromes Study Group
CARS  Coumadin Aspirin Reinfarction Study
CHAMP  Combination Hemotherapy and
Mortality Prevention
CI  confidence interval
DUCCS-II  Duke University Clinical Cardiology
Group Study-II
ECG  electrocardiographic
GUSTO IIb  Global Use of Strategies to open
Occluded coronary Arteries
HR  hazard ratio
MI  myocardial infarction
PURSUIT  Platelet Glycoprotein IIb/IIIa in
Unstable Angina: Receptor Suppression
Using Integrelin Therapy
TxA2  thromboxane A2ist, eptifibatide, or placebo. In both trials the randomized dnfusions were continued until hospital discharge or for a
aximum of 72 h. In PURSUIT aspirin doses between 80
nd 325 mg were recommended. No recommendations on
spirin dose were made in GUSTO IIb. Initial and subse-
uent in-hospital aspirin dose was recorded in GUSTO IIb.
nitial and discharge aspirin dose was recorded in PUR-
UIT. The subsequent in-hospital aspirin dose recorded in
USTO IIb was assumed to be the discharge dose for the
urpose of this analysis. Coronary revascularization proce-
ures and other treatments were performed at the discretion
f the treating physician.
nd points. The primary end point of our analysis was the
ccurrence of the combined end point of death, MI, or
troke between hospital discharge and six months follow-
p. Secondary end points included the individual compo-
ents of the primary end point. In GUSTO IIb, in North
merica and Australia, all suspected ischemic events be-
ween discharge and 30 days were adjudicated by a clinical
vents committee. In Europe, ischemic events within 30
ays were reviewed by an on-site medical monitor. In
URSUIT all MIs and stroke occurring within the first 30
ays were adjudicated by a clinical events committee. The
Is between day 30 and 6 months were confirmed but not
djudicated.
tatistical analysis. For the demographic, treatment, and
edication summaries, categorical data are presented as
requencies and percentages and continuous data are pre-
ented as medians and interquartile ranges. Chi-square tests
ere used to compare frequencies and Wilcoxon two-
ample tests were used to compare the continuous variables.
aplan-Meier methods were used to estimate the unad-
usted six-month event rates and log-rank tests were used to
ormally compare the groups.
In order to adjust for potential bias in the choice of
ischarge aspirin dose, a logistic model was used to calculate
propensity score (or probability) that a patient would
eceive a discharge aspirin dose of 150 mg. All demo-
raphic/baseline factors in addition to initial aspirin dose
150 mg vs. 150 mg), pre-randomization, index hospi-
alization and discharge medications, and index hospitaliza-
ion procedures were considered as possible predictors in the
ogistic model. Two-way interactions between all factors
ere also evaluated. The ability of the model to discriminate
etween patients discharged while receiving 150 mg
ersus 150 mg aspirin was assessed with the c-statistic
equivalent to the area under the receiver operating charac-
eristic curve).
Multiple Cox proportional hazards models of the primary
nd point and the individual components of this end point
ere developed. To account for patients who died early and
herefore did not have a chance to experience an MI or
troke, patients who died without experiencing an event
efore the median time to the event were removed from the
I and stroke analyses (MI, median time to event 36 days,
75 patients removed; stroke, median time to event 68.5
ays, 333 patients removed). All demographic and baseline
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Aspirin Dose in Acute Coronary Syndromes March 17, 2004:972–8actors, index hospitalization and discharge medications,
nd hospitalization procedures, as well as the propensity
core for aspirin dose, were used in the development of the
nd point models. For continuous variables, if the effect of
he variable on the end point was not linear, a cut point was
etermined in order to fit two linear splines that were then
sed in the models. For the evaluation of region, the U.S.
as used as the reference group. Two-way interactions
etween aspirin dose and all factors plus other selected
wo-way interactions were also evaluated. From the adjusted
odels, hazard ratios (HRs), 95% confidence intervals (CI)
f the HRs, and Wald chi-square p values are reported.
To examine the effect of the missing data on the
ropensity and end point models, data were imputed using
edians for the continuous data and modes for the cate-
orical factors. For each outcome, two models were gener-
ted using both imputed and non-imputed variables and the
esults were compared. The impact of the missing data was
egligible, as the results of the imputed and non-imputed
odels were nearly identical. Further, the influence of
ischarge aspirin dose on outcome did not change between
he imputed and non-imputed models. Therefore, the
esults from the imputed models are provided.
To further evaluate the relationship between aspirin dose
nd outcome, patients who received a discharge aspirin dose
150 mg were matched with patients that received a dose
150 mg on the basis of similar propensity scores. To
etermine the matched cohort, patients with propensity
cores within 0.01 were randomly matched using a 1:1 ratio.
ox proportional hazards models were then developed
ithin the matched patient cohort and the HRs from these
odels were compared with those from the overall models.
For all models, trial (PURSUIT vs. GUSTO IIb) was
ncluded as a blocking factor as well as a potential covariate.
AS Version 8 Software (Cary, North Carolina) was used to
erform all statistical analyses.
ESULTS
nformation on discharge aspirin dose and six-month isch-
Figure 1. Distribution of aspirin dosesmic outcomes was available for 20,521 patients: 96.0% i11,184 of 11,647) of the initial GUSTO IIb population
urviving to hospital discharge and 87.9% (9,337 of 10,624)
f the initial PURSUIT population surviving to hospital
ischarge. A discharge aspirin dose150 mg was prescribed
o 29.9% (n  6,128) of patients. The distribution of
ischarge aspirin doses in the two trials is presented in
igure 1. Baseline characteristics according to aspirin dose
re presented in Table 1. There was significant imbalance
etween the two groups. Patients receiving the higher
spirin dose were younger and more likely to have a history
f hypertension, diabetes, hypercholesterolemia, tobacco use
r previous MI, coronary artery bypass graft, or coronary
ngioplasty. In addition, patients discharged while receiving
150 mg of aspirin were more likely to have ST-segment
levation on their qualifying ECG, rales, and an MI as their
nrollment event. A greater proportion of patients receiving
he lower aspirin dose were participants in the PURSUIT
rial. The majority of patients receiving the lower aspirin
ose were recruited in Europe. Apart from beta-blockers
nd lipid-lowering agents, discharge medications were sim-
lar in the two groups.
ix-month outcome. At six months 1,310 patients had a
rimary event. There was no effect of greater aspirin dose on
he combined primary end point of six-month death, MI, or
troke (HR 1.06 [95% CI 0.94 to 1.19], p  0.35) by
nivariate analysis. The individual frequencies of death or
I were similar in the two treatment groups; however,
troke was more frequent with the higher aspirin dose
Table 2).
ropensity analysis. Significant predictors of discharge
spirin included in the multivariable logistic propensity
odel are presented in Table 3. The c-statistic, or area
nder the receiver operating characteristic curve, was 0.859.
his indicates that the model discriminated well between
atients discharged while receiving the different aspirin
oses.
ultivariable analysis of six-month outcome. Important
ultivariable predictors of six-month death, MI, and
troke are presented in Table 4. After adjustment for
e GUSTO IIb and PURSUIT trials.in thmbalance between the two aspirin groups in these
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March 17, 2004:972–8 Aspirin Dose in Acute Coronary Syndromesariables and the propensity for a discharge aspirin dose
150 mg, there was no effect of greater discharge aspirin
ose on the combined primary end point (HR 0.92 [95%
I 0.79 to 1.07], p  0.28). However, the higher aspirin
ose was associated with a reduction in six-month MI
HR 0.79 [95% CI 0.64 to 0.98], p  0.03) but a trend
owards higher stroke (HR 1.59 [95% CI 0.95 to 2.65], p
0.08). Aspirin dose did not affect the individual end
able 1. Demographic and Treatment Details
<150 mg
(n  6,128)
>150 mg
(n  14,341)
USTO IIb* 2,990 (48.8) 8,194 (56.9)
URSUIT* 3,138 (51.2) 6,199 (43.1)
tudy drug*
Eptifibatide 1,770 (28.9) 3,485 (24.2)
Hirudin 1,449 (23.6) 4,056 (28.2)
Heparin 2,909 (47.5) 6,852 (47.6)
ge (interquartile range)* 65 (56–72) 63.2 (54–71)
emale 1,986 (32.4) 4,504 (31.3)
aucasian* 5,924 (96.8) 12,792 (88.9)
egion*
U.S. 463 (7.6) 6,393 (44.4)
Canada 16 (0.3) 1451 (10.1)
Latin America 62 (1.0) 448 (3.1)
Western Europe 4,876 (79.6) 4,147 (28.8)
Eastern Europe 513 (8.4) 970 (6.7)
Australia/New Zealand 198 (3.2) 984 (6.8)
ypertension* 2,703 (44.1) 7,385 (51.3)
iabetes* 1,085 (17.7) 2,934 (20.4)
urrent smoker* 1,965 (32.2) 5,012 (34.9)
ypercholesterolemia* 2,283 (37.4) 6,007 (42.0)
revious MI* 1,952 (31.9) 4,873 (33.9)
rior stroke 133 (2.2) 356 (2.5)
rior PTCA* 1533 (25.0) 5065 (35.2)
rior CABG* 1,170 (19.1) 3,298 (22.9)
nrollment MI* 3,058 (49.9) 7,786 (54.2)
ualifying ECG
ST-segment elevation* 1,617 (26.4) 4,359 (30.3)
T-wave inversion* 2,808 (45.9) 6,370 (44.3)
ST-segment depression* 3,294 (53.8) 7,039 (49.0)
eripheral vascular disease 468 (7.6) 1,146 (8.0)
edications on discharge
ACE inhibitor 1,700 (27.8) 3,918 (27.2)
Beta-blockers* 3,762 (61.6) 8,473 (59.0)
Calcium blockers 2,038 (33.3) 4,806 (33.4)
Lipid-lowering agent* 1,046 (17.1) 2,670 (18.6)
Nitrates 3,400 (55.6) 7,869 (54.8)
p  0.05. Data are presented as n (%).
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft;
CG  electrocardiogram; MI  myocardial infarction; PTCA  percutaneous
ransluminal coronary angioplasty.
Table 2. Ischemic Outcomes at Six-Month Fo
Aspirin < 150 m
n/N (KM Est)
Death, MI, or stroke 374/6,128 (6.21
Death 194/6,107 (3.22
MI 209/6,084 (3.50
Stroke 28/6,019 (0.48
Data are presented as n (%).
MI  myocardial infarction.oint of six-month mortality (HR 0.89 [95% CI 0.72 to
.10], p  0.30, Fig. 2).
atched propensity analysis. In order to better adjust for
he baseline imbalances between the groups, patients were
atched on the basis of propensity score in a 1-to-1 fashion.
his limited the analysis to 8,531 patients with 492 events.
hese patients were well matched on the basis of baseline
haracteristics. In this matched analysis, there was no
ifference in the incidence of the composite endpoint death,
I, or stroke at six months (HR 0.94 [95% CI 0.80 to
.12], p  0.51). The effect of aspirin dose on the
ix-month MI (HR 0.83 [95% CI 0.66 to 1.05], p  0.12)
as no longer evident; however, doses 150 mg were
ssociated with an increase in the risk of six-month stroke
HR 1.74 [95% CI 1.01 to 3.02], p  0.05, Fig. 3).
ISCUSSION
n this, the largest study to date examining the relationship
etween aspirin dose and clinical outcome after ACS, we
bserved no difference in the combined incidence of death,
I, or stroke among patients discharged while receiving
150 mg versus 150 mg per day. Aspirin doses between
5 and 325 mg are currently recommended after an episode
f unstable angina or acute MI (2,3). Doses at the lower end
f this range are often advocated in order to limit gastroin-
estinal toxicity (4). The evidence to support these recom-
endations is drawn from controlled trials of daily aspirin
oses of 75 mg (n  796) (19), 160 mg (n  17,187) (20),
24 mg (n 1,266) (21), 650 mg (n 484) (22), and 1,300
g (n  555) (23). However, little is known of the
omparative efficacy of aspirin doses within this range.
here have been only two small studies that have directly
ompared aspirin dose in patients with ACS: the Duke
niversity Clinical Cardiology Group Study-II (DUCCS-
I, n  162) and the Aspirin at Low Dose in Unstable
ngina (ALDUSA) pilot study (n 112). The DUCCS-II
tudy compared the efficacy of low (81 mg) and intermediate
325 mg) aspirin doses in patients with acute MI treated
ith front loaded tissue-plasminogen activator (tPA) or
nisoylated plasminogen streptokinase activator complex
APSAC) (9), whereas the ALDUSA pilot study compared
aily aspirin doses of 325 mg and 40 mg. Both failed to
emonstrate an effect of aspirin dose on outcome but were
onsiderably underpowered to do so. The combination of
ow-dose aspirin (80 to 81 mg) and warfarin has been
Up
Aspirin >150 mg
p Valuen/N (KM Est)
936/14,393 (6.61) 0.34
433/14,360 (3.06) 0.50
515/14,262 (3.69) 0.61
102/14,169 (0.74) 0.04llow-
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Aspirin Dose in Acute Coronary Syndromes March 17, 2004:972–8ompared to intermediate (160 to 325 mg) doses in two
arger trials, the Coumadin Aspirin Reinfarction Study
CARS, n  8,803) (24) and the Combination Hemo-
herapy and Mortality Prevention (CHAMP, n  5,059)
tudy (25), and in the small (n  93) pilot trial of the
ntithrombotic therapy in Acute Coronary Syndromes
tudy Group (ATACS) (26). These trials failed to demon-
trate an effect of aspirin dose on outcome; however, the use
f warfarin in the low-dose aspirin arms may have con-
ounded the comparison of aspirin dose in these trials.
In the recent Antithrombotic Trialists’ Collaboration (1),
he proportional reduction in vascular events was equivalent
Table 3. Variables Included in the Propensity
Od
PURSUIT (vs. GUSTO IIb)
Region of enrollment
Canada
Latin America
Western Europe
Eastern Europe
Australia
Female (vs. male)
Age
65 (linear spline)
65 (linear spline)
Weight
80 (linear spline)
80 (linear spline)
Systolic blood pressure
140 (linear spline)
140 (linear spline)
Diastolic blood pressure
80 (linear spline)
80 (linear spline)
Heart rate
T-wave inversion on qualifying ECG
Hypertension
Previous angina
Peripheral vascular disease
Hypercholesterolemia
History of MI
Prior congestive heart failure
Initial aspirin dose 150 (vs. 150)
ACE inhibitor at baseline
Beta blocker therapy at baseline
Lipid-lowering therapy at baseline
In-hospital lipid-lowering therapy
ACE inhibitor at discharge
Beta-blockers at discharge
Lipid-lowering therapy at discharge
Thrombolysis administered
In-hospital PTCA
In-hospital CABG
PURSUIT/qualifying ECG T-wave*
PURSUIT/previous angina*
PURSUIT/thrombolysis*
Female/thrombolysis*
*Interactions.
CI  confidence interval; other abbreviations as in Tableor doses of 75 to 150 mg, 160 to 325 mg, and 500 to 1,500 Tg daily. However, the majority of the data used in this
nalysis was drawn from trials of low-dose aspirin in
erebrovascular or peripheral vascular disease. Here aspirin
oses as low as 30 to 50 mg daily (5,8) have been extensively
tudied and provide equivalent protection from death,
on-fatal stroke, or MI as higher doses. Kong et al. (27),
sing random effects models, have re-examined the Anti-
hrombotic Trialist’s data. In an unadjusted analysis they
emonstrate a lesser effect with increasing aspirin dose,
mphasizing the uncertainty. Thus, in the absence of
efinitive data it has been assumed that the efficacy of
ow-dose aspirin is equivalent in different vascular beds.
ysis for Discharge Aspirin Doses 150 mg
atio 95% CI p Value
6 (0.38–0.55)  0.001
9 (3.00–8.30)  0.001
2 (0.38–0.72)  0.001
5 (0.05–0.06)  0.001
5 (0.13–0.18)  0.001
9 (0.24–0.36)  0.001
3 (0.75–0.92)  0.001
9 (0.99–1.00) 0.016
9 (0.99–1.01) 0.833
9 (0.98–0.99)  0.001
0 (0.99–1.01) 0.848
0 (0.99–1.00) 0.084
0 (0.99–1.00) 0.018
1 (1.01–1.02)  0.001
0 (1.00–1.01) 0.207
0 (0.99–1.00) 0.042
9 (0.71–0.89)  0.001
1 (1.02–1.21) 0.017
0 (0.71–0.90)  0.001
4 (1.08–1.44) 0.003
7 (1.08–1.28)  0.001
5 (1.05–1.26) 0.002
(0.70–0.96) 0.012
(11.59–15.11)  0.001
(1.08–1.36) 0.001
(1.02–1.21) 0.017
(1.00–1.38) 0.046
(0.53–0.79)  0.001
(0.82–0.99) 0.023
(0.76–0.89)  0.001
(1.00–1.46) 0.050
(0.66–0.86)  0.001
(1.20–1.45)  0.001
(0.59–0.76)  0.001
(1.13–1.55)  0.001
(1.02–1.47) 0.027
(1.19–2.78) 0.006
(0.58–0.94) 0.014Anal
ds R
0.4
4.9
0.5
0.0
0.1
0.2
0.8
0.9
0.9
0.9
1.0
1.0
1.0
1.0
1.0
1.0
0.7
1.1
0.8
1.2
1.1
1.1
0.82
13.23
1.21
1.11
1.18
0.65
0.90
0.82
1.21
0.76
1.32
0.67
1.32
1.22
1.82
0.74his assumption may not be entirely valid, as platelet
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March 17, 2004:972–8 Aspirin Dose in Acute Coronary Syndromesctivation is enhanced in unstable angina or acute MI and
he risk of recurrent ischemic events is high in this popu-
ation (10).
Aspirin exerts its antithrombotic effect through irrevers-
ble inhibition of the enzyme cyclo-oxygenase-1 (28), also
eferred to as prostaglandin H synthase. Aspirin acetylates a
erine residue within the active site of the enzyme prevent-
ng access of its substrate arachidonic acid thus inhibiting
he production of thromboxane A2 (TxA2), a potent
latelet agonist. Aspirin doses 100 mg provide near
omplete suppression (95  4%) of TxA2 production in
lotted whole blood in healthy individuals (29). However,
ersistent TxA2 production, as evidenced by urinary excre-
ion of TxA2 metabolites, has been documented in up to
0% of ACS patients despite aspirin therapy (11). This
ailure to achieve complete inhibition of TxA2 production,
ften referred to as “aspirin resistance,” has recently been
inked to adverse clinical outcome (14). In the Heart
utcomes Prevention Evaluation (HOPE) study, elevated
rinary concentrations of 11-dehydro thromboxane B2, a
table metabolite of TxA2, were associated with an in-
able 4. Important Multivariable Predictors of Six-Month
eath, MI, or Stroke
Predictor Hazard Ratio 95% CI
URSUIT 1.26 1.10–1.43
egion of enrollment
Western Europe 0.74 0.59–0.94
emale 0.81 0.71–0.92
ualifying ECG ST depression 1.34 1.20–1.51
nrollment MI 1.31 1.17–1.47
resence of rales 1.17 1.01–1.36
enal insufficiency 2.11 1.46–3.05
iabetes 1.54 1.36–1.74
revious angina 1.36 1.18–1.58
eripheral vascular disease 1.18 1.00–1.40
istory of MI 1.50 1.34–1.68
rior stroke 1.56 1.22–1.99
urrent smoker 1.35 1.18–1.54
n-hospital PTCA 0.73 0.63–0.84
n-hospital CABG 0.45 0.36–0.55
n addition to the propensity score, the adjusted model included Canada, Latin
merica, Eastern Europe, Australia, age, weight, systolic blood pressure, heart rate,
amily history of CAD, in-hospital ACE and discharge lipid lowering therapy.
Abbreviations as in Tables 1 and 3.
igure 2. Multivariate adjusted hazard ratios for six-month death, non-
patal myocardial infarction (MI), and stroke. CI  confidence interval.reased risk of cardiovascular death and MI (13). The cause
f aspirin resistance is unknown; however, aspirin’s inhibi-
ion of urinary thromboxane B2 excretion is dose dependent
etween 20 mg and 325 mg of aspirin (15), and in some
ituations ex vivo evidence of aspirin resistance can be
vercome by increasing dose (16). Although these data
ould suggest that aspirin doses 150 mg might be
articularly important in ACS, where aspirin resistance is
ommon, we observed no significant benefit yet significantly
reater risk with higher aspirin doses. Other investigators
30,31) have performed analyses of aspirin dose on adverse
utcome after an ACS. In an analysis of more than 12,000
atients in the CURE trial, low-dose aspirin (100 mg)
as associated with a substantially lower risk of bleeding.
imilarly, in a meta-analysis of more than 300,000 patients,
erebrauny et al. (31) observed that higher aspirin doses
ere associated with more frequent bleeding. Unfortu-
ately, data on long-term bleeding were not recorded in
URSUIT and GUSTO IIb. It remains plausible that, in
ur study, higher aspirin dose was associated with an
ncrease in six-month stroke in unadjusted and matched
nalyses as a result of increased bleeding risk.
Our findings are non-randomized and cannot be consid-
red conclusive. It is possible that patients perceived to be at
ncreased risk of stroke were prescribed a higher dose of
spirin. Furthermore, we cannot exclude dose changes or
ariation in compliance after discharge. For example, the
atients in the lower aspirin dose may have been prescribed
he lower dose because of intolerance and potentially been
ess compliant. These limitations emphasize the need for a
arge dedicated randomized trial to fully examine this issue.
lthough the effect of aspirin dose on outcome may be
mall, it is important to realize that it may have profound
mplications because of the high prevalence of coronary
rtery disease and associated aspirin use. There is evidence
hat aspirin’s gastrointestinal side effects are dose dependent
32), higher doses being associated with increased risk. The
ecent CURE trial findings in a large cohort reinforce the
iability of higher dose aspirin, such as 325 mg, for predis-
igure 3. Hazard ratios for six-month death, non-fatal myocardial infarc-
ion (MI), and stroke after matching on the basis of the propensity score.
I  confidence interval.osition to bleeding complications.
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Aspirin Dose in Acute Coronary Syndromes March 17, 2004:972–8onclusions. In this pooled analysis of more than 20,000
atients with unstable angina or acute MI, we observed no
ifference in the incidence of death but, potentially, less
requent MI and more frequent stroke among patients
ischarged while receiving higher aspirin doses. Given the
normous epidemic of atherosclerosis and its complications,
dentifying the appropriate dose of aspirin in the low-dose
ange could have a much larger impact on death and
isability than many newer treatments.
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